Summary of mouse phenotypes
| . | CD19Cre/+ . | CD19Cre/+KrasG12D/+ . | CD19Cre/+Ink4a/Arf L/+ . | CD19Cre/+KrasG12D/+Ink4a/Arf L/+ . |
|---|---|---|---|---|
| Premalignant | ||||
| Number of mice | 3 | 3 | 3 | 3 |
| Spleen weight, mg | 127 ± 12 | 194 ± 6** | 173 ± 12** | 213 ± 6**†* |
| Spleen cells × 107 | 10.6 ± 0.6 | 14.0 ± 0.8** | 12.6 ± 1.2 (ns) | 16.5 ± 1.0**†* |
| Malignant | ||||
| No. of mice | 10 | 20 | 20 | 26 |
| Lymphoma type | None(10 of 10) | Low-grade B lymphoma(8 of 20) | Pre-B-ALL(12 of 20) | Pre-B-ALL(26 of 26) |
| . | CD19Cre/+ . | CD19Cre/+KrasG12D/+ . | CD19Cre/+Ink4a/Arf L/+ . | CD19Cre/+KrasG12D/+Ink4a/Arf L/+ . |
|---|---|---|---|---|
| Premalignant | ||||
| Number of mice | 3 | 3 | 3 | 3 |
| Spleen weight, mg | 127 ± 12 | 194 ± 6** | 173 ± 12** | 213 ± 6**†* |
| Spleen cells × 107 | 10.6 ± 0.6 | 14.0 ± 0.8** | 12.6 ± 1.2 (ns) | 16.5 ± 1.0**†* |
| Malignant | ||||
| No. of mice | 10 | 20 | 20 | 26 |
| Lymphoma type | None(10 of 10) | Low-grade B lymphoma(8 of 20) | Pre-B-ALL(12 of 20) | Pre-B-ALL(26 of 26) |
Engineered mice of the indicated genotypes were analyzed before overt malignancy (premalignant; 8 weeks of age) or following development of leukemia/lymphoma (malignant). For spleen weight and cell number, the standard deviation is provided.
ns, not significant.
P values were calculated relative to CD19Cre/+ or CD19Cre/+Ink4a/Arf L/+ (†) using Welch’s t test. *P ≤ .05; **P ≤ .01.